查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1555474

流感药物市场，按药物类型、按流感类型、按年龄层、按给药途径、按配销通路和按地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Influenza Medications Market, By Drug Type, By Influenza Type, By Age Group, By Route of Administration, By Distribution Channel and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 399 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年流感药物市场规模为9.3243亿美元，2024年至2032年复合年增长率为7.2%。

流感药市场-市场动态

流感发病率的增加预计将推动市场的成长

流感是一种季节性復发的疾病，每年都会在全球不同地区爆发。流感季节期间发病率较高，导致对药物干预措施的需求增加。此外，零星的流感大流行或流行病会大大增加流感的发生率，导致抗病毒治疗和预防策略的需求激增。美国疾病管制与预防中心 (CDC) 估计，本季流感导致至少 3,500 万例、40 万人住院治疗和 25,000 人死亡。此外，抗病毒药物和综合治疗方法开发的进步为市场带来了巨大的成长机会。儘管如此，与新药相关的高成本可能会对市场扩张带来挑战。

流感药物市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 7.2% 左右的复合年增长率成长

根据药物类型细分，预计抗病毒药物将在 2023 年呈现最大市场份额

根据流感类型细分，甲型流感是 2023 年的主要类型

依年龄组别划分，2023年成人为主导类型

根据给药途径细分，2023年口服是领先类型

从配销通路细分来看，医院药局是2023年的主导类型

按地区划分，北美是 2023 年的主要收入来源

流感药物市场-細項分析：

全球流感药物市场根据药物类型、流感类型、年龄层、给药途径、配销通路和地区进行细分。

依药物类型，市场分为三类：抗病毒药物、抗组织胺、镇痛解热药。抗病毒药物在市场上占据主导地位。这些药物的配方是为了减轻流感症状的强度和持续时间，在某些情况下，它们还可以避免併发症。

根据流感类型，市场分为两个部分：甲型流感和乙型流感。它因其在引发每年流感流行中的作用而受到认可，并且由于其快速突变能力而具有导致大流行的能力。

市场依年龄层分为三个部分：成人、儿童和老年。成人细分市场占据主导地位。鑑于成年人经常经历季节性流感，且疾病的严重程度受到年龄、潜在健康状况和疫苗接种史等因素的影响，因此以成人为重点的流感药物市场是关键部分。

根据给药途径，市场分为三类：口服、吸入和静脉注射。口服品类在市场上占主导地位。口服抗病毒药物通常是对抗流感的主要选择，特别是在治疗轻度至中度病例时。

根据配销通路，市场分为三个不同的类别：医院药房、零售药房和线上药房。医院药房占据市场主导地位。医院需要有效的抗病毒治疗来照顾严重后果风险增加的患者，包括老年人、已有健康状况的人和免疫系统受损的人。

流感药物市场 - 地理洞察

市场地域广阔，涵盖北美、拉丁美洲、欧洲、亚太地区、中东和非洲。这些领域根据对商业活动做出贡献的国家进一步分类。在先进药物疗法的采用增加和医疗保健支出增加的推动下，北美引领市场。北美，特别是美国的监管框架有利于新流感治疗方法的快速批准和实施。这包括获得其他地区可能尚无法获得的创新疗法。根据美国国家癌症中心报告，2022年，共有37种新药（称为新药）在美国首次获得批准。健康统计。由于意识的提高和早期诊断，欧洲成为第二大市场扩张地区。

流感药物市场-竞争格局：

流感药物市场表现出高度的竞争力，其特点是许多製药公司努力争取更大的份额，特别是在抗病毒领域。本次竞赛的一个重要焦点在于采用独特作用机制的新型抗病毒药物的创新。那些分配资源用于研发以製定能够克服抗药性并提供增强功效或便利的先进流感疗法的公司正在策略性地定位自己，以抓住未来的市场机会。此外，这些公司正在努力在新兴市场建立强大的影响力，这些市场人口众多且流感发病率不断上升，带来了巨大的销售潜力。公司之间也共同努力提高人们对早期抗病毒干预优势的认识，特别是在流感季节。

最新进展：

2024 年 5 月，阿斯特捷利康将于 5 月在加州圣地牙哥举行的美国胸腔科学会 (ATS) 国际会议上展示其着名的吸入、生物和早期呼吸产品组合的新临床和现实世界发现2024 年5月17 日至5 月22 日。的未满足需求，以及患有其他慢性呼吸道疾病。

2023 年 10 月，赛诺菲和 Teva Pharmaceutical Industries Ltd. 的美国子公司 Teva Pharmaceuticals 宣布建立合作伙伴关係，旨在共同开发和共同商业化资产 TEV'574。该资产目前正在进行 2b 期临床试验，用于治疗溃疡性结肠炎和克隆氏症，这两种疾病都是发炎性肠道疾病。

目录

第一章：流感药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类型分類的流感药物市场片段
    • 按流感类型分類的流感药物市场片段
    • 按年龄分類的流感药物市场片段
    • 按给药途径分類的流感药物市场摘要
    • 按配销通路分類的流感药物市场片段
    • 按国家/地区分類的流感药物市场摘要
    • 按地区分類的流感药物市场片段
  • 竞争洞察

第 3 章：流感药物主要市场趋势

  • 流感药物市场驱动因素
    • 市场驱动因素的影响分析
  • 流感药物市场限制
    • 市场限制影响分析
  • 流感药物市场机会
  • 流感药物市场未来趋势

第 4 章：流感药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：流感药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：流感药物市场格局

  • 2023 年流感药物市场占有率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：流感药物市场 - 依药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 抗病毒药物
      • 单一抗病毒药物
      • 联合抗病毒药物
    • 抗组织胺药
    • 止痛药
    • 退烧药

第 8 章：流感药物市场 - 按流感类型

  • 概述
    • 按流感类型分類的细分市场份额分析
    • 甲型流感
    • 乙型流感

第 9 章：流感药物市场 - 按年龄组

  • 概述
    • 按年龄组别分類的细分市场占有率分析
    • 成年人
    • 儿科
    • 老年科

第 10 章：流感药物市场 - 依给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 口服
    • 吸入
    • 静脉

第 11 章：流感药物市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 12 章：流感药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美流感药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类型）
    • 北美市场规模与预测（按流感类型）
    • 北美市场规模和预测（按年龄组）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲流感药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类型）
    • 欧洲市场规模与预测（按流感类型）
    • 欧洲市场规模和预测（按年龄层）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区流感药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类型）
    • 亚太地区市场规模与预测（按流感类型）
    • 亚太地区市场规模与预测（依年龄层）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲流感药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类型）
    • 拉丁美洲市场规模与预测（按流感类型）
    • 拉丁美洲市场规模与预测（按年龄层）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲流感药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类型）
    • 中东和非洲市场规模及预测（按流感类型）
    • 中东和非洲市场规模及预测（按年龄层）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 13 章：主要供应商分析 - 流感药物产业

  • 竞争仪表板
  • 公司简介
    • AstraZeneca plc
    • Teva Pharmaceutical Industries Ltd
    • BioCryst Pharmaceuticals, Inc.
    • Sanofi
    • Daiichi Sankyo Company
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • NATCO Pharma Limited
    • GlaxoSmithKline plc
    • Lupin
    • Others

第 14 章：360 度分析师视角

第 15 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV3636

REPORT HIGHLIGHT

Influenza Medications Market size was valued at USD 932.43 million in 2023, expanding at a CAGR of 7.2% from 2024 to 2032.

Medications for influenza are utilized to either treat or prevent infections caused by the flu. Antiviral drugs that target influenza viruses serve as a crucial complement to the influenza vaccine in managing the disease. These antiviral agents function by hindering the replication of the influenza virus, which in turn alleviates the severity and shortens the duration of symptoms. Their efficacy is maximized when administered promptly, preferably within 48 hours of the onset of symptoms. Thus, influenza medications play a vital role in alleviating flu symptoms and mitigating the overall effects of the infection.

Influenza Medications Market- Market Dynamics

The increasing incidence of influenza is expected to drive the growth of the market

Influenza is a recurring illness that manifests seasonally, resulting in annual outbreaks across various regions globally. The heightened occurrence during the flu season leads to an increased demand for pharmaceutical interventions. Additionally, sporadic flu pandemics or epidemics can considerably elevate the incidence of influenza, resulting in surges in the need for antiviral therapies and preventive strategies. The Centers for Disease Control and Prevention (CDC) estimates that this season has witnessed at least 35 million cases, 400,000 hospitalizations, and 25,000 fatalities attributed to the flu. Moreover, advancements in the development of antiviral medications and integrated treatment methodologies present significant growth opportunities for the market. Nonetheless, the high costs associated with novel medications may pose challenges to market expansion.

Influenza Medications Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.2% over the forecast period (2024-2032)

Based on Drug Type segmentation, Antiviral drugs were predicted to show maximum market share in the year 2023

Based on Influenza Type segmentation, Influenza A was the leading type in 2023

Based on Age Group segmentation, Adults were the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Distribution Channel segmentation, Hospital pharmacies were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Influenza Medications Market- Segmentation Analysis:

The Global Influenza Medications Market is segmented based on Drug Type, Influenza Type, Age Group, Route of Administration, Distribution Channel, and Region.

The market is segmented into three classifications according to Drug Type: Antiviral drugs, Antihistamines, and Analgesics and Antipyretics. Antiviral drugs hold a dominant position in the market. These drugs are formulated to alleviate the intensity and length of flu symptoms, and in certain instances, they may also avert complications.

The market is classified into two segments according to the influenza type: Influenza A and Influenza B. Influenza A holds a predominant position in the market. It is recognized for its role in triggering yearly flu epidemics and possesses the capacity to result in pandemics owing to its rapid mutation capabilities.

The market is classified into three segments according to age groups: Adults, Pediatric, and Geriatric. The Adult segment dominates the market. The Influenza Medications Market focused on adults represents a crucial segment, given that adults frequently experience seasonal influenza, with the severity of the illness influenced by factors such as age, underlying health conditions, and vaccination history.

The market is segmented into three categories according to the route of administration: Oral, Inhaled, and Intravenous. The Oral category holds a dominant position in the market. Oral antiviral medications are frequently the primary option for combating influenza, especially in the treatment of mild to moderate cases.

The market is segmented into three distinct categories according to the Distribution Channel: Hospital pharmacies, Retail pharmacies, and online pharmacies. Hospital pharmacies dominate the market. Hospitals necessitate efficient antiviral treatments to care for patients who are at an increased risk of severe outcomes, including the elderly, individuals with pre-existing health conditions, and those with compromised immune systems.

Influenza Medications Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads the market, driven by an increase in the adoption of advanced drug therapies and a rise in healthcare spending. The regulatory framework in North America, especially in the United States, facilitates the expedited approval and implementation of new influenza treatments. This includes access to innovative therapies that may not yet be accessible in other regions. In 2022, a total of 37 new drugs, referred to as novel drugs, were approved for the first time in the U.S. Additionally, previously approved drugs were authorized for new applications, including new indications and patient demographics, as reported by the National Center for Health Statistics. Europe positions as the second largest region for market expansion, attributed to increasing awareness and early diagnosis.

Influenza Medications Market- Competitive Landscape:

The Influenza Medications Market exhibits a high level of competitiveness, characterized by numerous pharmaceutical firms striving to secure a larger share, especially within the antiviral sector. A significant focus of this competition lies in the innovation of new antiviral medications that employ unique mechanisms of action. Firms that allocate resources towards research and development to formulate advanced influenza therapies capable of overcoming resistance and providing enhanced efficacy or convenience are strategically positioning themselves to seize future market opportunities. Additionally, these companies are working to establish a robust presence in emerging markets, where a substantial population and a rising incidence of influenza present considerable sales potential. There is also a concerted effort among companies to promote awareness regarding the advantages of early antiviral intervention, particularly during the flu season.

Recent Developments:

In May 2024, AstraZeneca is set to present new clinical and real-world findings from its prominent inhaled, biologic, and early-stage respiratory portfolio at the American Thoracic Society (ATS) International Conference, taking place in San Diego, CA, from May 17 to May 22, 2024. The company will unveil 59 abstracts, which include 12 late-breaking posters, concentrating on the unmet needs associated with chronic obstructive pulmonary disease (COPD), severe asthma, and eosinophilic granulomatosis with polyangiitis (EGPA), along with other chronic respiratory conditions.

In October 2023, Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announced a partnership aimed at the co-development and co-commercialization of the asset TEV'574. This asset is presently undergoing Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, both of which are forms of inflammatory bowel disease.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INFLUENZA MEDICATIONS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AstraZeneca plc
  • Teva Pharmaceutical Industries Ltd
  • BioCryst Pharmaceuticals, Inc.
  • Sanofi
  • Daiichi Sankyo Company
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • NATCO Pharma Limited
  • GlaxoSmithKline plc
  • Lupin
  • Others

GLOBAL INFLUENZA MEDICATIONS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antiviral Drugs
  • Single Antiviral Drugs
  • Combination Antiviral Drugs
  • Antihistamines
  • Analgesics
  • Antipyretics

GLOBAL INFLUENZA MEDICATIONS MARKET, BY INFLUENZA TYPE- MARKET ANALYSIS, 2019 - 2032

  • Influenza A
  • Influenza B

GLOBAL INFLUENZA MEDICATIONS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Adults
  • Pediatric
  • Geriatric

GLOBAL INFLUENZA MEDICATIONS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Inhaled
  • Intravenous

GLOBAL INFLUENZA MEDICATIONS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL INFLUENZA MEDICATIONS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Influenza Medications Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Influenza Medications Market Snippet by Drug Type
    • 2.1.2. Influenza Medications Market Snippet by Influenza Type
    • 2.1.3. Influenza Medications Market Snippet by Age Group
    • 2.1.4. Influenza Medications Market Snippet by Route of Administration
    • 2.1.5. Influenza Medications Market Snippet by Distribution Channel
    • 2.1.6. Influenza Medications Market Snippet by Country
    • 2.1.7. Influenza Medications Market Snippet by Region
  • 2.2. Competitive Insights

3. Influenza Medications Key Market Trends

  • 3.1. Influenza Medications Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Influenza Medications Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Influenza Medications Market Opportunities
  • 3.4. Influenza Medications Market Future Trends

4. Influenza Medications Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Influenza Medications Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Influenza Medications Market Landscape

  • 6.1. Influenza Medications Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Influenza Medications Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 7.1.2. Antiviral Drugs
      • 7.1.2.1. Single Antiviral Drugs
      • 7.1.2.2. Combination Antiviral Drugs
    • 7.1.3. Antihistamines
    • 7.1.4. Analgesics
    • 7.1.5. Antipyretics

8. Influenza Medications Market - By Influenza Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Influenza Type, 2023 & 2032 (%)
    • 8.1.2. Influenza A
    • 8.1.3. Influenza B

9. Influenza Medications Market - By Age Group

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Age Group, 2023 & 2032 (%)
    • 9.1.2. Adults
    • 9.1.3. Pediatric
    • 9.1.4. Geriatric

10. Influenza Medications Market - By Route of Administration

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 10.1.2. Oral
    • 10.1.3. Inhaled
    • 10.1.4. Intravenous

11. Influenza Medications Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Hospital Pharmacies
    • 11.1.3. Retail Pharmacies
    • 11.1.4. Online Pharmacies

12. Influenza Medications Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Influenza Medications Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Influenza Medications Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Influenza Medications Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Influenza Medications Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Influenza Medications Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Influenza Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Influenza Medications Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. AstraZeneca plc
    • 13.2.2. Teva Pharmaceutical Industries Ltd
    • 13.2.3. BioCryst Pharmaceuticals, Inc.
    • 13.2.4. Sanofi
    • 13.2.5. Daiichi Sankyo Company
    • 13.2.6. Novartis AG
    • 13.2.7. F. Hoffmann-La Roche AG
    • 13.2.8. NATCO Pharma Limited
    • 13.2.9. GlaxoSmithKline plc
    • 13.2.10. Lupin
    • 13.2.11. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us